Nothing Special   »   [go: up one dir, main page]

WO1998050079A3 - Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes - Google Patents

Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes Download PDF

Info

Publication number
WO1998050079A3
WO1998050079A3 PCT/US1998/008848 US9808848W WO9850079A3 WO 1998050079 A3 WO1998050079 A3 WO 1998050079A3 US 9808848 W US9808848 W US 9808848W WO 9850079 A3 WO9850079 A3 WO 9850079A3
Authority
WO
WIPO (PCT)
Prior art keywords
heart failure
vivo delivery
ventricular remodeling
compositions
techniques
Prior art date
Application number
PCT/US1998/008848
Other languages
French (fr)
Other versions
WO1998050079A2 (en
Inventor
H Kirk Hammond
Tamsin L Kelly
Original Assignee
Univ California
H Kirk Hammond
Tamsin L Kelly
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, H Kirk Hammond, Tamsin L Kelly filed Critical Univ California
Priority to EP98918904A priority Critical patent/EP0980428A2/en
Priority to AU71735/98A priority patent/AU7173598A/en
Priority to JP54824398A priority patent/JP2002515065A/en
Priority to CA2289600A priority patent/CA2289600C/en
Priority to EA199901002A priority patent/EA005157B1/en
Publication of WO1998050079A2 publication Critical patent/WO1998050079A2/en
Publication of WO1998050079A3 publication Critical patent/WO1998050079A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Methods are provided for treating patients with congestive heart failure (including dilated cardiomyopathy and congestive heart failure associated with severe coronary artery disease), and for preventing or alleviating deleterious ventricular remodeling after myocardial infarction. The preferred methods of the present invention involve in vivo delivery of genes encoding angiogenic proteins or peptides to the myocardium by direct injection of a vector containing the gene into a blood vessel supplying the heart.
PCT/US1998/008848 1997-05-06 1998-04-30 Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes WO1998050079A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP98918904A EP0980428A2 (en) 1997-05-06 1998-04-30 TECHNIQUES AND COMPOSITIONS FOR TREATING HEART FAILURE AND VENTRICULAR REMODELING BY $i(IN VIVO) DELIVERY OF ANGIOGENIC TRANSGENES
AU71735/98A AU7173598A (en) 1997-05-06 1998-04-30 Techniques and compositions for treating heart failure and ventricular remodeling by (in vivo) delivery of angiogenic transgenes
JP54824398A JP2002515065A (en) 1997-05-06 1998-04-30 Techniques and compositions for treating heart failure and ventricular reconstitution by in vivo delivery of an angiogenic transgene
CA2289600A CA2289600C (en) 1997-05-06 1998-04-30 Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
EA199901002A EA005157B1 (en) 1997-05-06 1998-04-30 Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85277997A 1997-05-06 1997-05-06
US08/852,779 1997-05-06

Publications (2)

Publication Number Publication Date
WO1998050079A2 WO1998050079A2 (en) 1998-11-12
WO1998050079A3 true WO1998050079A3 (en) 1999-02-04

Family

ID=25314196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/008848 WO1998050079A2 (en) 1997-05-06 1998-04-30 Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes

Country Status (8)

Country Link
EP (1) EP0980428A2 (en)
JP (1) JP2002515065A (en)
KR (2) KR20010012313A (en)
CN (1) CN1267331A (en)
AU (1) AU7173598A (en)
CA (1) CA2289600C (en)
EA (1) EA005157B1 (en)
WO (1) WO1998050079A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8636998B2 (en) 2008-02-19 2014-01-28 Celladon Corporation Method for enhanced uptake of viral vectors in the myocardium

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2329934A1 (en) * 1998-05-30 1999-12-09 Collateral Therapeutics, Inc. Methods of altering cardiac cell phenotype
DE19915485A1 (en) 1999-04-07 2000-10-19 Hugo A Katus Heart failure therapy
EP1225921A1 (en) * 1999-11-05 2002-07-31 The Regents of the University of California TECHNIQUES AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE BY i IN VIVO /i GENE DELIVERY
AU2002216751A1 (en) * 2000-06-30 2002-01-14 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use
KR100562824B1 (en) 2002-03-20 2006-03-23 주식회사 바이로메드 Hybrid hepatocyte growth factor gene which has a high expression efficiency and expresses two heterotypes of hepatocyte growth factor
CA2682160C (en) 2007-04-11 2017-04-04 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
RU2470995C2 (en) 2008-04-09 2012-12-27 Вайромед Ко., Лтд. Lyophilised dna compounds for increased plasmid dna expression
WO2009132457A1 (en) 2008-05-02 2009-11-05 University Of Western Ontario Fgf-9 and its use relating to blood vessels
US20150118287A1 (en) * 2012-02-14 2015-04-30 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
MX2016005006A (en) 2013-10-22 2016-07-14 Viromed Co Ltd Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor.
US11554179B2 (en) 2018-07-19 2023-01-17 Helixmith Co., Ltd Lyophilized pharmaceutical compositions for naked DNA gene therapy
CN109517807A (en) * 2018-11-20 2019-03-26 暨南大学 A kind of phage vector and application thereof of cardiovascular targeting
CA3133981A1 (en) * 2019-03-17 2020-09-24 Baylor College Of Medicine Direct reprogramming of cardiac fibroblasts into cardiomyocytes using an endothelial cell transdifferentiation strategy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026742A1 (en) * 1995-02-28 1996-09-06 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GIORDANO ET AL: "INTRACORONARY GENE TRANSFER OF FIBROBLAST GROWTH FACTOR-5 INCREASES BLOOD FLOW AND CONTRACTILE FUNCTION IN AN ISCHEMIC REGION OF THE HEART", NATURE MEDICINE, vol. 2, 1996, pages 534 - 539, XP002074003 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8636998B2 (en) 2008-02-19 2014-01-28 Celladon Corporation Method for enhanced uptake of viral vectors in the myocardium

Also Published As

Publication number Publication date
WO1998050079A2 (en) 1998-11-12
CN1267331A (en) 2000-09-20
AU7173598A (en) 1998-11-27
CA2289600C (en) 2010-06-29
KR20010012313A (en) 2001-02-15
JP2002515065A (en) 2002-05-21
EA199901002A1 (en) 2000-08-28
EP0980428A2 (en) 2000-02-23
EA005157B1 (en) 2004-12-30
KR20070005030A (en) 2007-01-09
CA2289600A1 (en) 1998-11-12

Similar Documents

Publication Publication Date Title
WO2002089856A8 (en) Techniques and compositions for treating cardiovascular disease by (in vivo) gene delivery
WO1998050079A3 (en) Techniques and compositions for treating heart failure and ventricular remodeling by in vivo delivery of angiogenic transgenes
Koh et al. Long-term survival of AT-1 cardiomyocyte grafts in syngeneic myocardium
EP0837629A4 (en) Pericardial therapeutic and diagnostic agent delivery
EP0760682A4 (en) Gene transfer-mediated angiogenesis therapy
WO1997026337B1 (en) Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions
WO2002064157A3 (en) Localized myocardial injection method for treating ischemic myocardium
CA2243261A1 (en) Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions
CN101925362A (en) Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor
Tao et al. Angiopoietin-1 enhanced myocyte mitosis, engraftment, and the reparability of hiPSC-CMs for treatment of myocardial infarction
AU2001294096A1 (en) Adeno-associated virus-mediated delivery of angiogenic factors
EA200200533A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE IN VIVO DELIVERY OF GENES
JP4843817B2 (en) Heart failure treatment
Iwai et al. Genes up-regulated in hypertrophied ventricle
Hinkel et al. C-terminal variable AGES domain of Thymosin β4: the molecule's primary contribution in support of post-ischemic cardiac function and repair
WO2000025804A3 (en) A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure
BRPI0718679A2 (en) COMPOUND, DNA MOLECULE, AND, METHODS TO TREAT A PATIENT WITH DAMAGED HEART TISSUE, TO TREAT A PATIENT TO REPAIR DAMAGED CARTILAGE AND TO TREAT A PATIENT TO REPAIR DAMAGED NERVE TISSUE
JP2003513942A5 (en)
EA019099B1 (en) Method for targeted transgene delivery in myocardium of a patient with myocardial ischemia
WO1998010085A3 (en) Gene therapy for congestive heart failure
Chachques et al. Dynamic cardiomyoplasty for long-term cardiac assist
Matsuo et al. Molecular biology of atrial natriuretic peptides
WO2003000009A2 (en) Stimulation of vascularization with vegf-b
Jayasankar et al. Targeted overexpression of growth hormone by adenoviral gene transfer preserves myocardial function and ventricular geometry in ischemic cardiomyopathy
WO2001048164A3 (en) Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09068102

Country of ref document: US

Ref document number: 98806526.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2289600

Country of ref document: CA

Ref document number: 2289600

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997010265

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1998918904

Country of ref document: EP

Ref document number: 71735/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 199901002

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1998918904

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997010265

Country of ref document: KR